Innovative Industrial Properties (IIPR) investor relations material

Executive summary

• Q3 revenue was $64.9M; net income attributable to common stockholders was $28.7M, or $0.99 per diluted share, and AFFO was $54.8M, or $1.96 per share.

• Leasing and life science investments advanced, including $275M of Q3 commitments; fully funded life science investments are projected to contribute ~26% of annualized income.

• The portfolio comprised 108 properties across 19 states, with $2.9B of total invested capital at September 30, 2026.

Financial highlights

• Q3 revenue was $64.9M versus $64.7M YoY; net income attributable to common stockholders was $28.7M versus $28.3M, and diluted EPS was $0.99 versus $0.97.

• Q3 diluted AFFO was $1.96 per share versus $1.71 YoY; normalized FFO was $1.80 per share versus $1.60.

• Q3 AFFO was $54.8M versus $53.0M in Q2; past-due rent recoveries contributed $0.15 per share, including non-recurring benefits from selected tenants.

• 9M common net income rose to $99.5M from $83.7M; 9M diluted AFFO was $5.66 per share versus $5.35.

• Q3 interest and other income was $14.3M, primarily reflecting IQHQ investment income; IQHQ interest and dividend income was $10.4M.

Outlook and guidance

• The remaining $134M Alewife Park commitment is expected to be funded through Q4 2027, subject to conditions; the loan is expected to yield 15.8% on average, subject to a 14% floor.

• The Alewife loan matures in February 2028 with a one-year extension option; an option allows up to $155M of additional notes on the same terms, subject to conditions.

• Cash, operating cash flows, borrowing capacity and net proceeds from financing offerings are expected to cover anticipated needs for at least 12 months.

• Prospective leases and replacement-tenant arrangements depend on due diligence, licensing, regulatory approvals, receivership outcomes and other contingencies.